Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Therapeutic Drug Carrier Systems
Fator do impacto: 2.9 FI de cinco anos: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Imprimir: 0743-4863
ISSN On-line: 2162-660X

Volumes:
Volume 37, 2020 Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2013005589
pages 51-90

Options and Opportunities for Clinical Management and Treatment of Psoriasis

Udita Agrawal
Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H. S. Gour Vishwavidyalaya, Sagar-470003 M.P. India
Madhu Gupta
Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H. S. Gour Vishwavidyalaya, Sagar-470003 M.P. India
Nil
Devyani Dube
ISF College of Pharmacy
Suresh P. Vyas
Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H. S. Gour Vishwavidyalaya, Sagar-470003 M.P. India

RESUMO

Psoriasis is a complex, multifactorial disease that appears to be influenced by immune-mediated components. For many years the pathogenesis of psoriasis has been discordant; the clinical picture suggested that the psoriasis was secondary to abnormal keratinocyte proliferation and differentiation, but later the role of the T cell was revealed. A variety of treatment options range from topical agents (e.g., coal tar, dithranol, and emollients for milder forms) to systemic agents (i.e., methotrexate or cyclosporin), and phototherapy. Recently, biologics have been added to this list that target particular steps in the immune or inflammatory pathways. Various nanocarriers (e.g., liposomes, niosomes, and microemulsions) have been successfully exploited for the delivery of several antipsoriatic drugs. This review provides insight into various psoriasis treatment strategies−from conventional to novel−currently in use or in development as well as the novel targets that have been explored and/or investigated for anti-psoriatic therapy. The pathogenesis of psoriasis and some of the topical, systemic biological, and novel approaches currently in use or in development are reviewed here. The pros and cons of each treatment strategy are presented, as are some of the animal models used to study features reminiscent of psoriasis. This information can be used to better the understanding of treatment options for this disease.


Articles with similar content:

Psoriasis Clinical Implications and Treatment: A Review
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 3
Ashlesha S. Raut, Vandana B. Patravale, Rashmi H. Prabhu
Druggable Targets in Pancreatic Adenocarcinoma
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Cristina Napoli, Stefania Nobili, Ida Landini, Gabriele Perrone, Enrico Mini, Renato Tassi
Critical Aspects in Rationale Design of Fluorouracil-Based Adjuvant Therapies for the Management of Colon Cancer
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 2
Vivek Ranjan Sinha, Honey
Role of Block Copolymer Nanoconstructs in Cancer Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.26, 2009, issue 2
H. G. Agrawal, K. K. Upadhyay, C. Schatz, Sebastian Lecommandoux, J. F. Le Meins, Ambikanandan Misra, C. Upadhyay
Oral Colon-Specific Drug Delivery of Protein and Peptide Drugs
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 1
Ruchita V. Kumar, Sanjay Singh, Vivek Ranjan Sinha, J. R. Bhinge, Asmita Singh, Rachana Kumria